Pii‐20 View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-02

AUTHORS

F. A. Jong, T. Scott‐Horton, D. L. Kroetz, H. L. McLeod, L. E. Friberg, R. H. Mathijssen, J. Verweij, A. Sparreboom, S. Marsh

ABSTRACT

PK variability of the anticancer agent CPT-11 is high. Life-threatening grade 3-4 diarrhea is seen in up to 25% of patients and has been related with CPT-11 PK and UGT1A1-status. Aim of this study was to evaluate the association of ABCC2 polymorphisms and haplotypes with CPT-11 disposition and diarrhea. 105 European Caucasian cancer patients who were previously assessed for CPT-11 PK (90-min infusion; three-weekly), toxicity and UGT1A1*28, were genotyped for ABCC2 using Pyrosequencing (table 1). Frequencies of wild type alleles and haplotypes (13 identified in 85 patients) are given in table 1. ABCC2*1 was associated with slower CPT-11 clearance (28.4 vs 33.9 L/h; P=.005). In 67 patients who received the recommended single agent dose (350 mg/m2 or 600 mg), ABCC2*1 was negatively correlated with grade 3–4 diarrhea (P=.040). A 3-fold reduced risk (30% vs 10%) was unrelated to UGT1A1*28 since severe diarrhea manifested itself in particular in patients homozygous for the UGT1A1*1 allele (P=.011). This study suggests that the ABCC2*1 haplotype is associated with CPT-11 related diarrhea, maybe as a consequence of altered CPT-11 excretion via the bile into the gut, and hence less local activation into the active metabolite, SN-38. As its protective effect on diarrhea is seen predominantly in patients not at risk for diarrhea due to UGT1A1*28, additional studies of the relationships of ABCC2 genotypes to CPT-11 PK and toxicity are warranted. Clinical Pharmacology & Therapeutics (2005) 79, P41–P41; doi: 10.1016/j.clpt.2005.12.145 More... »

PAGES

p41-p41

Identifiers

URI

http://scigraph.springernature.com/pub.10.1016/j.clpt.2005.12.145

DOI

http://dx.doi.org/10.1016/j.clpt.2005.12.145

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009032255


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jong", 
        "givenName": "F. A.", 
        "id": "sg:person.016461601737.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016461601737.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scott\u2010Horton", 
        "givenName": "T.", 
        "id": "sg:person.01314176545.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314176545.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kroetz", 
        "givenName": "D. L.", 
        "id": "sg:person.0620612751.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620612751.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McLeod", 
        "givenName": "H. L.", 
        "id": "sg:person.0621173744.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621173744.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Friberg", 
        "givenName": "L. E.", 
        "id": "sg:person.0703300175.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703300175.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mathijssen", 
        "givenName": "R. H.", 
        "id": "sg:person.010050000177.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010050000177.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Verweij", 
        "givenName": "J.", 
        "id": "sg:person.01236641403.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236641403.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sparreboom", 
        "givenName": "A.", 
        "id": "sg:person.016247331557.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016247331557.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC \u2010 Daniel den Hoed Cancer Center Rotterdam The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marsh", 
        "givenName": "S.", 
        "id": "sg:person.01231016344.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231016344.35"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-02", 
    "datePublishedReg": "2006-02-01", 
    "description": "PK variability of the anticancer agent CPT-11 is high. Life-threatening grade 3-4 diarrhea is seen in up to 25% of patients and has been related with CPT-11 PK and UGT1A1-status. Aim of this study was to evaluate the association of ABCC2 polymorphisms and haplotypes with CPT-11 disposition and diarrhea. 105 European Caucasian cancer patients who were previously assessed for CPT-11 PK (90-min infusion; three-weekly), toxicity and UGT1A1*28, were genotyped for ABCC2 using Pyrosequencing (table 1). Frequencies of wild type alleles and haplotypes (13 identified in 85 patients) are given in table 1. ABCC2*1 was associated with slower CPT-11 clearance (28.4 vs 33.9 L/h; P=.005). In 67 patients who received the recommended single agent dose (350 mg/m2 or 600 mg), ABCC2*1 was negatively correlated with grade 3\u20134 diarrhea (P=.040). A 3-fold reduced risk (30% vs 10%) was unrelated to UGT1A1*28 since severe diarrhea manifested itself in particular in patients homozygous for the UGT1A1*1 allele (P=.011). This study suggests that the ABCC2*1 haplotype is associated with CPT-11 related diarrhea, maybe as a consequence of altered CPT-11 excretion via the bile into the gut, and hence less local activation into the active metabolite, SN-38. As its protective effect on diarrhea is seen predominantly in patients not at risk for diarrhea due to UGT1A1*28, additional studies of the relationships of ABCC2 genotypes to CPT-11 PK and toxicity are warranted. Clinical Pharmacology & Therapeutics (2005) 79, P41\u2013P41; doi: 10.1016/j.clpt.2005.12.145", 
    "genre": "non_research_article", 
    "id": "sg:pub.10.1016/j.clpt.2005.12.145", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "79"
      }
    ], 
    "name": "PII\u201020", 
    "pagination": "p41-p41", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2b07c61aeb91eb893b6c077b4a4bb730b2cb81ae5035f9b202dff87053ff0473"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1016/j.clpt.2005.12.145"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009032255"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1016/j.clpt.2005.12.145", 
      "https://app.dimensions.ai/details/publication/pub.1009032255"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000015.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://onlinelibrary.wiley.com/doi/10.1016/j.clpt.2005.12.145/abstract"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2005.12.145'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2005.12.145'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2005.12.145'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2005.12.145'


 

This table displays all metadata directly associated to this object as RDF triples.

132 TRIPLES      20 PREDICATES      27 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1016/j.clpt.2005.12.145 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4ea83a4f899742d5b6e2a923c0da963c
4 schema:datePublished 2006-02
5 schema:datePublishedReg 2006-02-01
6 schema:description PK variability of the anticancer agent CPT-11 is high. Life-threatening grade 3-4 diarrhea is seen in up to 25% of patients and has been related with CPT-11 PK and UGT1A1-status. Aim of this study was to evaluate the association of ABCC2 polymorphisms and haplotypes with CPT-11 disposition and diarrhea. 105 European Caucasian cancer patients who were previously assessed for CPT-11 PK (90-min infusion; three-weekly), toxicity and UGT1A1*28, were genotyped for ABCC2 using Pyrosequencing (table 1). Frequencies of wild type alleles and haplotypes (13 identified in 85 patients) are given in table 1. ABCC2*1 was associated with slower CPT-11 clearance (28.4 vs 33.9 L/h; P=.005). In 67 patients who received the recommended single agent dose (350 mg/m2 or 600 mg), ABCC2*1 was negatively correlated with grade 3–4 diarrhea (P=.040). A 3-fold reduced risk (30% vs 10%) was unrelated to UGT1A1*28 since severe diarrhea manifested itself in particular in patients homozygous for the UGT1A1*1 allele (P=.011). This study suggests that the ABCC2*1 haplotype is associated with CPT-11 related diarrhea, maybe as a consequence of altered CPT-11 excretion via the bile into the gut, and hence less local activation into the active metabolite, SN-38. As its protective effect on diarrhea is seen predominantly in patients not at risk for diarrhea due to UGT1A1*28, additional studies of the relationships of ABCC2 genotypes to CPT-11 PK and toxicity are warranted. Clinical Pharmacology & Therapeutics (2005) 79, P41–P41; doi: 10.1016/j.clpt.2005.12.145
7 schema:genre non_research_article
8 schema:inLanguage en
9 schema:isAccessibleForFree false
10 schema:isPartOf N813727b172e84670b0a448cbf61848fd
11 Nab40fed129254c16b7fea5a262ddd4d8
12 sg:journal.1017409
13 schema:name PII‐20
14 schema:pagination p41-p41
15 schema:productId N378bf9ead4b24908a8182454a1114504
16 N80d7f25e48ad4ca6a3abdd20fd59c079
17 Nd8f3a915d28b4265bf4a53286c30b244
18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009032255
19 https://doi.org/10.1016/j.clpt.2005.12.145
20 schema:sdDatePublished 2019-04-10T21:57
21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
22 schema:sdPublisher Neac7367e3af9442bbb9e441d6bd8490e
23 schema:url http://onlinelibrary.wiley.com/doi/10.1016/j.clpt.2005.12.145/abstract
24 sgo:license sg:explorer/license/
25 sgo:sdDataset articles
26 rdf:type schema:ScholarlyArticle
27 N01707a1d1a924484b61efce3278a5fe8 rdf:first sg:person.01231016344.35
28 rdf:rest rdf:nil
29 N0a5ec2a5ce944587b7de79bc01504a1e rdf:first sg:person.0621173744.43
30 rdf:rest N3c8f4e2c94354c978f040550b7b893f7
31 N24ee3e82edf544e4b5d87aa1b58015b7 schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
32 rdf:type schema:Organization
33 N378bf9ead4b24908a8182454a1114504 schema:name doi
34 schema:value 10.1016/j.clpt.2005.12.145
35 rdf:type schema:PropertyValue
36 N3b69dd280c5d4d219ef8066a1f49eca1 schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
37 rdf:type schema:Organization
38 N3c8f4e2c94354c978f040550b7b893f7 rdf:first sg:person.0703300175.07
39 rdf:rest Ne2ac490f3f914ea5aa9109e06daef384
40 N4479943dd75349eaa81365fda043fe46 schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
41 rdf:type schema:Organization
42 N482eef1f2dba4a29b5c3f551264bd2b4 rdf:first sg:person.0620612751.83
43 rdf:rest N0a5ec2a5ce944587b7de79bc01504a1e
44 N4ea83a4f899742d5b6e2a923c0da963c rdf:first sg:person.016461601737.92
45 rdf:rest Ne88ecb60e15943b39cc6f53c8e437237
46 N5ebea3a4f8124977b1fc3d958a9ff7e1 schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
47 rdf:type schema:Organization
48 N6b5dbe018bb844938e27fe2aa57f85ed schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
49 rdf:type schema:Organization
50 N6dc3bc8dbf6a418bbfa0508fb8d74b3e schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
51 rdf:type schema:Organization
52 N80d7f25e48ad4ca6a3abdd20fd59c079 schema:name readcube_id
53 schema:value 2b07c61aeb91eb893b6c077b4a4bb730b2cb81ae5035f9b202dff87053ff0473
54 rdf:type schema:PropertyValue
55 N813727b172e84670b0a448cbf61848fd schema:volumeNumber 79
56 rdf:type schema:PublicationVolume
57 Nab40fed129254c16b7fea5a262ddd4d8 schema:issueNumber 2
58 rdf:type schema:PublicationIssue
59 Nbd4d4248800b416fb668c939440b64b2 rdf:first sg:person.01236641403.86
60 rdf:rest Nee15791bf0864a02b9e460f89ce60c7a
61 Nc3e71b1f50db4ddeaa90df4ed13a5bec schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
62 rdf:type schema:Organization
63 Nd3429de98b9c433c9c335cecdfffbf49 schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
64 rdf:type schema:Organization
65 Nd8f3a915d28b4265bf4a53286c30b244 schema:name dimensions_id
66 schema:value pub.1009032255
67 rdf:type schema:PropertyValue
68 Ne2ac490f3f914ea5aa9109e06daef384 rdf:first sg:person.010050000177.67
69 rdf:rest Nbd4d4248800b416fb668c939440b64b2
70 Ne88ecb60e15943b39cc6f53c8e437237 rdf:first sg:person.01314176545.44
71 rdf:rest N482eef1f2dba4a29b5c3f551264bd2b4
72 Neac7367e3af9442bbb9e441d6bd8490e schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 Nee15791bf0864a02b9e460f89ce60c7a rdf:first sg:person.016247331557.17
75 rdf:rest N01707a1d1a924484b61efce3278a5fe8
76 Nf5c734db38884759ba17fac3e97965a2 schema:name Washington University School of Medicine, University of California, Uppsala University, National Cancer Institute Erasmus MC ‐ Daniel den Hoed Cancer Center Rotterdam The Netherlands
77 rdf:type schema:Organization
78 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
79 schema:name Medical and Health Sciences
80 rdf:type schema:DefinedTerm
81 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
82 schema:name Clinical Sciences
83 rdf:type schema:DefinedTerm
84 sg:journal.1017409 schema:issn 0009-9236
85 1532-6535
86 schema:name Clinical Pharmacology & Therapeutics
87 rdf:type schema:Periodical
88 sg:person.010050000177.67 schema:affiliation Nd3429de98b9c433c9c335cecdfffbf49
89 schema:familyName Mathijssen
90 schema:givenName R. H.
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010050000177.67
92 rdf:type schema:Person
93 sg:person.01231016344.35 schema:affiliation Nc3e71b1f50db4ddeaa90df4ed13a5bec
94 schema:familyName Marsh
95 schema:givenName S.
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231016344.35
97 rdf:type schema:Person
98 sg:person.01236641403.86 schema:affiliation N24ee3e82edf544e4b5d87aa1b58015b7
99 schema:familyName Verweij
100 schema:givenName J.
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236641403.86
102 rdf:type schema:Person
103 sg:person.01314176545.44 schema:affiliation N6dc3bc8dbf6a418bbfa0508fb8d74b3e
104 schema:familyName Scott‐Horton
105 schema:givenName T.
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314176545.44
107 rdf:type schema:Person
108 sg:person.016247331557.17 schema:affiliation N6b5dbe018bb844938e27fe2aa57f85ed
109 schema:familyName Sparreboom
110 schema:givenName A.
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016247331557.17
112 rdf:type schema:Person
113 sg:person.016461601737.92 schema:affiliation N3b69dd280c5d4d219ef8066a1f49eca1
114 schema:familyName Jong
115 schema:givenName F. A.
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016461601737.92
117 rdf:type schema:Person
118 sg:person.0620612751.83 schema:affiliation Nf5c734db38884759ba17fac3e97965a2
119 schema:familyName Kroetz
120 schema:givenName D. L.
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620612751.83
122 rdf:type schema:Person
123 sg:person.0621173744.43 schema:affiliation N4479943dd75349eaa81365fda043fe46
124 schema:familyName McLeod
125 schema:givenName H. L.
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621173744.43
127 rdf:type schema:Person
128 sg:person.0703300175.07 schema:affiliation N5ebea3a4f8124977b1fc3d958a9ff7e1
129 schema:familyName Friberg
130 schema:givenName L. E.
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703300175.07
132 rdf:type schema:Person
 




Preview window. Press ESC to close (or click here)


...